LY255283 is selective, competitive antagonist of BLT2 receptors (IC50 values are ~ 1 and > 10 μM at human recombinant BLT2 and BLT1 receptors respectively), and inhibits LTB4-induced contraction of lung parenchyma (pA2 = 7.2), and reduces LTB4-mediated airway obstruction in guinea pigs following i.v. and oral administration.

CP-105696是一种选择性白三烯 B4 (LTB4) 受体拮抗剂，IC50 为 8.42 nM。

Ablukast (Ro 23-3544) 是一种特异性的白三烯受体拮抗剂，有效减少 LTC4 和抗原诱导的支气管收缩。Ablukast 是一种 LTD4 受体拮抗剂。

Montelukast是一种半胱氨酸白三烯受体1(CysLT1) 拮抗剂，广泛用于哮喘和过敏性疾病的预防与治疗，具有重要的临床应用。

Olsalazine是一种有效抑制巨噬细胞趋化 LTB4 的药物，IC50 为 0.39 mM，并可减少多形核白细胞 (PMNL) 和单核细胞 (MNL) 中的 5-HETE、11-HETE、12-HETE 和 15-HETE 合成，适用于溃疡性结肠炎的研究，具有抗炎活性。

MK-571 Sodium is a competitive, potent and selective LTD4 antagonist with Ki values of 0.22 nM.

Cromoglicic acid is used to treat the symptoms of asthma.

LY293111 is a potent LTB4 receptor antagonist with IC50 values of 17.6nM and 6.3nM for inhibition of the specific binding of radiolabeled-LTB4 to isolated human neutrophils and the LTB4-induced chemotaxis of human neutrophils, respectively.

Zafirlukast is the first-approved LTR antagonist with anti-asthmatic and potential capsular contracture-preventing activities.

Montelukast Sodium is a potent, selective and competitive LTR1 antagonist with IC50 value < 5 nM, possesssing anti-inflammatory and bronchodilating activities.

Pranlukast 是一种选择性的 CysLT1 受体拮抗剂，对 CysLT1 受体具有高亲和力，IC50 值为 0.5 nM。Pranlukast 具有抗过敏和抗哮喘作用，可用于过敏性疾病和哮喘的研究。